arrow
Y

Yun Cheng

Daiichi Sankyo, Inc.
H指数:22
被引数:1,823

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparing subcutaneous vs intravenous amivantamab with lazertinib in EGFR-mutated advanced NSCLC: Analysis of Asian patients from PALOMA-3

比较皮下注射与静脉注射阿曼曲单抗联合拉泽替尼在EGFR突变晚期NSCLC中的疗效:PALOMA-3研究中亚洲患者分析

2024-12-010
PRE
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Amivantamab联合lazertinib与osimertinib治疗具有高危疾病生物标志物的一线EGFR突变晚期非小细胞肺癌: 来自MARIPOSA的二次分析

2024-09-015
OAAI
Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
2023-10-0114
PRE